Monday, 23 September 2019

Brii Biosciences builds innovative pipeline

10 December 2018 | News

Enters into clinical collaboration with VBI Vaccines and expands partnership with Vir Biotechnology.

Zhi Hong, Ph.D., co-founder and CEO, Brii Biosciences

Zhi Hong, Ph.D., co-founder and CEO, Brii Biosciences

Brii Biosciences, a company committed to serving patients’ needs and improving public health in China, has announced several research collaborations that significantly advance its efforts to develop innovative medicines to meet the unique needs of patients in China.

These collaborations include two clinical development programs focused on hepatitis B virus (HBV) infection and China-based exclusive research agreements to develop novel immunotherapeutics to treat infectious diseases and other immune dysfunctions.

In addition, the company has formally established its research and development headquarters in Beijing and has forged a public-private partnership to promote public health and develop translational research capabilities.



× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Survey Box

Is Pharma innovation getting inhibited in APAC?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls